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The proteolipid protein gene (PLP) is normally present at chromosome Xq22. Mutations and duplications of this
gene are associated with Pelizaeus-Merzbacher disease (PMD). Here we describe two new families in which males
affected with PMD were found to have a copy of PLP on the short arm of the X chromosome, in addition to a
normal copy on Xq22. In the first family, the extra copy was first detected by the presence of heterozygosity of
the AhaII dimorphism within the PLP gene. The results of FISH analysis showed an additional copy of PLP in
Xp22.1, although no chromosomal rearrangements could be detected by standard karyotype analysis. Another
three affected males from the family had similar findings. In a second unrelated family with signs of PMD, cytogenetic
analysis showed a pericentric inversion of the X chromosome. In the inv(X) carried by several affected family
members, FISH showed PLP signals at Xp11.4 and Xq22. A third family has previously been reported, in which
affected members had an extra copy of the PLP gene detected at Xq26 in a chromosome with an otherwise normal
banding pattern. The identification of three separate families in which PLP is duplicated at a noncontiguous site
suggests that such duplications could be a relatively common but previously undetected cause of genetic disorders.
Introduction
Pelizaeus-Merzbacher disease (PMD [MIM 312080]) is
a rare X-linked dysmyelinating disorder of the CNS.
Clinical features of PMD include nystagmus, psycho-
motor developmental delay, spasticity, and ataxia, all of
which may also be present—but in a milder form—in
X-linked spastic paraplegia (SPG2 [MIM 312920]) (see
Hodes et al. 1993; Hodes 1998). Both conditions may
be caused by alterations in the coding region of PLP
(Hudson et al. 1989; Trofatter et al. 1989). These
changes include missense, deletion/insertion, and splice-
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site mutations (reviewed in Hodes [1998]; Hodes et al.
1993). Complete gene deletions (Raskind et al. 1991)
also cause the disorder. However, a considerable number
of affected boys, even those with clear X-linked family
pedigrees, appear to have no structural alterations of
PLP. Change in gene dosage has been shown to be an
additional and common cause of the disorder. Complete
duplications of PLP have been observed in a number of
affected males (Ellis and Malcolm 1994; Harding et al.
1995; Inoue et al. 1996; Nave and Boespflug-Tanguy
1996; Woodward et al. 1998). In fact, duplication of
PLP appears to be the single most common cause of
PMD/SPG2 (Sistermans et al. 1998; Woodward et al.
1998; Inoue et al. 1999).
The clinical findings associated with mutations of the
PLP gene are spread over a wide spectrum extending
from the very severe connatal PMD to the relatively
mild, later-onset SPG2. This has led us to designate the
condition as “PMD/SPG2” (Hodes 1998). The clinical
phenotype for patients with duplications may generally
be milder than that of patients with point mutations in
PLP (Sistermans et al. 1998; Inoue et al. 1999), whereas
patients with complete loss of PLP appear to be less
severely affected (Raskind et al. 1991).
In the present study, we report three families with
unusual duplications of PLP in which the additional
Hodes et al.: Disjoined Duplications in PMD/SPG2 15
copy is aberrantly located on the X chromosome. The
first family was discovered when a male with clinical
and radiological findings of PMD was found to be het-
erozygous for the AhaII dimorphism of exon 4 of PLP.
The results of examination by FISH showed copies of
PLP in chromosomes Xq22 and Xp22.1. The second
family was found after the propositus’s karyotype sug-
gested that an inversion might disrupt the gene, but
copies were found at both ends of the inversion by FISH.




Appropriate informed consent was obtained from all
subjects.
Family 1.—The propositus (patient IV-1; fig. 1A)
was a 6-year-old male who, at age 6 mo, was referred
to an ophthalmologist for congenital horizontal nys-
tagmus with fine, rapid eye movements that were
equal in all fields of gaze. Slight unsteadiness of the
head, which was not typical of the bobbing seen with
spasmus nutans, was noted. A CT scan was normal.
The diagnosis seemed to rest between congenital nys-
tagmus and, less likely, spasmus nutans. At age 10
mo, an elevated a-fetoprotein level prompted concern
about ataxia-telangiectasia, and the infant was re-
ferred to a neurologist. The neurologist noted that no
attempts at crawling or weight-bearing were made
when the infant was placed in a standing position, an
inability to maintain a sitting position for more than
5 s, truncal ataxia, no ankle clonus, deep tendon re-
flexes that were 3–4 plus, and a normal sensory ex-
amination. Magnetic-resonance imaging (MRI)
showed a high T2 signal throughout the white matter.
Electroencephalography results were abnormal due to
left temporal and occipital slowing, but no definite
seizure activity was noted. At age 15 mo, the child
could walk with holding. At age 19 mo, nystagmus,
wobbling, and truncal ataxia were still noted but were
ameliorating. Results of laboratory examinations in-
cluded a normal karyotype with no evidence of fragile
X syndrome, normal thyroid function, and normal
serum and urine amino acid screenings.
At age 8 years, height, weight, and occipitofrontal
circumference were all at !5th percentile. Speech was
deliberate. Nystagmus was intermittent, and clonus and
increasing contractures of the knees occurred. The pa-
tient could walk behind his wheelchair, with scissoring.
His vision seemed to be worsening. He played video
games and also played with LEGOs. He was repeating
the second grade and was “doing well.”
The paternal family history was not remarkable. On
the maternal side, there were numerous cases of mental
retardation and “cerebral palsy.” Epilepsy and, proba-
bly, congenital nystagmus were also noted, only in males.
The mother’s half brother (patient III-7; fig. 1A) was
seen at age 31 years. He had severe visual impairment,
incoordination with tremor, and spastic paraplegia. He
had been graduated from a special high school.
Family 2.—The propositus (patient II-3; fig. 1B) pre-
sented shortly after birth with features (dysmorphic fa-
cial features, microcephaly, right ventricular outflow-
tract obstruction, and ventricular septal defect) that were
suggestive of Down syndrome. At age 2 mo, he had
bilateral horizontal nystagmus superimposed on pen-
dular nystagmus. He had bilateral dysmetria and de-
creased tone reflexes. At age 6 mo, he had an episode
of apnea with asystole. At age 3 years, he was unable
to sit alone or to support his weight on his feet, and his
speech was limited. At age 7 years, he could not crawl
or walk. He had a marked increase in extensor tone in
the lower extremities and tightness of hip flexors, ham-
strings, and heel cords. The patient is, at present, of age
16.5 years and is wheelchair-bound.
The family history is outlined in fig. 1B. The father
(patient I-1; fig. 1B) and the mother (patient I-2) were
normal. A maternal uncle (patient I-6) has “cerebral
palsy,” the details of which are unknown. Maternal
grandparents were reported to be normal. One of the
propositus’s brothers (patient II-1) presented with nys-
tagmus at age 3 mo. Early motor milestones were nor-
mal, but, by 18 mo, he had an unsteady gait. The results
of ophthalmologic examination were consistent with
congenital idiopathic nystagmus without retinopathy. At
age 4 years, the patient walked by holding on but was
largely wheelchair-dependent. Speech was severely de-
layed. At age 8 years, he had pendular nystagmus at rest
and no marked titubation. Tone was slightly decreased
in the left arm, and he was bilaterally dysmetric (in the
left arm more than in the right arm). He walked with
support and had a wide-based gait. His reflexes were
increased in the lower extremities (in the left extremity
more than in the right extremity). The results of MRI
studies were consistent with a diffuse dysmyelinating dis-
order. Another brother (patient II-2) was normal neu-
rologically and developmentally at age 6 years. A third
brother (patient II-4) had nystagmus at age 2 mo. He
did not achieve normal milestones. By age 18 mo, his
gait was unsteady, and the results of ophthalmologic
examination were consistent with congenital idiopathic
nystagmus without retinopathy. By age 4 years, he was
largely wheelchair-dependent, and speech was severely
delayed. The results of MRI studies done at age 8 years
were consistent with a diffuse dysmyelinating disorder.
A sister (patient II-5) was normal neurologically at age
5 wk. She is, at present, of age 12.5 years and is well.
Families 1 and 2 have disparate karyotypic findings.
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Figure 1 Pedigrees of families 1 (A) and 2 (B)
It is also unlikely that they are distantly related, since
they have different racial origins.
Family 3.—Family 3 was previously described by
Woodward et al. (1998). There was no family history
of note. In the propositus, onset of nystagmus at age 2
mo and hypermetropia were noted. By age 1 year, the
propositus had head titubation and an upper-limb in-
tention tremor develop. By age 4 years, signs of spastic
paraparesis and mild scoliosis had developed. The pa-
tient has had no seizures. He sat unsupported at age 7
mo, crawled at 10 mo, pulled to stand at 14 mo, and
walked with aid at age 2 years, 3 mo. He had a vocab-
ulary of 50 words at age 2 years and was using 5-word
sentences by 4 years, and he follows the normal curric-
Hodes et al.: Disjoined Duplications in PMD/SPG2 17
ulum at school. The results of MRI of his brain, done
at 13 mo and 24 mo, showed high signal throughout
the supratentorial white matter on T2-weighted imaging
and a normal signal on T1-weighted imaging, which
were consistent with dysmyelination.
Molecular Studies
The following tests have previously been described:
SSCP analysis (Orita et al. 1989); DNA-sequence anal-
ysis (Trofatter et al. 1989); tests for the AhaII dimor-
phism (Trofatter et al. 1991); the CA-dinucleotide repeat
in the first intron of PLP (Mimault et al. 1995); the
MvaI polymorphism in exon 2 (Osaka et al. 1995); di-
gestion with restriction enzymes; and Southern blotting
(Sambrook et al. 1989).
Cytogenetic Analysis
Cytogenetic studies were performed on short-term
lymphocyte cultures or lymphoblastoid cell lines, by use
of standard techniques.
FISH
Families 1 and 3.—FISH was performed, as previously
described, with a cosmid (cU125A1) containing the PLP
gene and a control cosmid (cU144A10) mapping ∼850
kb distal to the PLP gene (Woodward et al. 1998). A
digoxigenin-labeled X chromosome–specific centromeric
probe was included to confirm hybridization efficiency
and X chromosome number. The cosmid probes were
detected with fluorescein isothiocyanate conjugated with
avidin, and the centromeric probe was detected with
rhodamine conjugated to antidigoxigenin. Cells were
counterstained with 4,6-diamidino-2-phenylindole and
were viewed with a Zeiss Axiophot fluorescent micro-
scope with a triple-band pass filter. Ten metaphase chro-
mosomes and 50 interphase nuclei were analyzed per
slide for both cosmid probes.
Family 2.—Three yeast artificial chromosomes (YACs
[122e11, 226c9, and 526g7]) containing the PLP gene
were identified by a computer search of the Human Ge-
nome Sequencing Center, Baylor College of Medicine
database. DNA was purified by standard techniques and
was labeled with biotin-16-dUTP by means of nick
translation (Oncor). Genomic probes (kindly provided
by Dr. Lynn Hudson) containing portions of the PLP
gene were also labeled with biotin-16-dUTP, for FISH
studies. Probe pJB008 contains a 9-kb BamHI fragment
of the human PLP gene that includes a portion of exon
1 and all of exon 2, and probe pJC102 contains a 9-kb
BamHI fragment that includes exons 5–7. FISH studies
were done by use of standard techniques.
Results
Family 1
Duplication of the AhaII dimorphic site and molec-
ular analyses.—Routine SSCP screening of the coding
region of PLP of the propositus (patient IV-1; fig. 1A)
showed a pattern consistent with heterozygosity for the
AhaII dimorphism—a result that is unique in our ex-
perience studying several hundred males, many of whom
have a diagnosis of PMD. DNA from a second blood
sample yielded identical results (fig. 2). DNA from three
other affected males (patients III-7, III-12, and IV-10;
fig. 1A) was also found to be heterozygous for the di-
morphism. The findings were confirmed by amplification
of exon 4, followed by sequencing of the exon, and by
the presence, in the propositus, of the dimorphism in
amplified fragments containing exons 3B–4, 4–5, and
4–6 (data not shown). The presence of heterozygosity
of the AhaII dimorphism implied duplication of the gene,
and this was consistent with results from multiplex PCR
analysis with PLP exon 4 primers and with primers for
the prion protein gene PRNP. Additional findings were
as follows: (a) Southern blotting of genomic DNA di-
gested with BamHI, EcoRI, HindIII, PstI, and XbaI and
probed with exons 4–5 showed only fragments of nor-
mal (expected) size, and (b) probing (with exons 4–5)
of pulsed-field gels of NotI-digested DNA showed a sin-
gle intense fragment (not shown). Taken together, these
results suggest that both copies of PLP are intact and
that a duplication encompasses both NotI sites.
Identification of the PLP duplication by FISH.—
Figure 3A and B shows the duplicated signals for a cos-
mid containing PLP, detected by FISH, in the propositus
(patient IV-1; fig. 1). The hybridization signals are shown
on chromosome Xq22 in the region expected for the
PLP gene (Willard and Riordan 1985; Mattei et al.
1986) and also on chromosome Xp22. A single PLP
signal is shown in figure 3D.
The PLP duplication was confirmed in interphase nu-
clei (fig. 3B) by the presence of two clearly resolvable
yellow signals. The control cosmid gave one signal,
thereby indicating that the DNA detected by that probe
was not duplicated. The duplication was also found by
FISH in both the patient’s mother and an uncle.
No inversion or any other rearrangement of the X
chromosome was found in the karyotype. Inversion was
further ruled out by FISH with a commercially available
probe to the XIST gene (results not shown). Character-
ization of the duplication by means of interphase FISH
showed that the proximal breakpoint lies350 kb from
the PLP gene (data not presented). This suggests that
both copies are intact.
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Figure 2 Separation of fragments of genomic DNA from family 1, after digestion by AhaII. Fragments of genomic DNA obtained by
PCR amplification of exon 4 were digested by AhaII. Electrophoresis of the digest was performed in a 12% polyacrylamide gel. Lane 1 denotes
a 100-bp ladder; lane 2, a male control who was AhaII negative; lane 3, a male control who was AhaII positive; lane 4, patient III-1; lane 5,
patient III-2; lane 6, patient IV-1; lane 7, patient IV-2; lane 8, patient IV-10; lane 9, patient III-12; lane 10, patient II-12; lane 11, a female
control who was heterozygous; and lane 12, distilled water.
Family 2
Cytogenetic analysis.—The initial cytogenetic anal-
ysis performed on the propositus demonstrated a per-
icentric inversion of the X chromosome (46,XY,
inv(X)(p11.4q22.1). The results of studies performed
on additional family members showed the same in-
version in the phenotypically normal mother (patient
I-2; fig. 1B) of the propositus, in an unaffected sister
(patient II-5), and in two affected brothers (patients
II-1 and II-4).
Molecular cytogenetic (FISH) studies were performed
with three PLP-containing YACs, to identify their po-
sition with respect to the inversion breakpoints. A signal
from each of the YACs was present on both the short
and long arms of the inverted X chromosome near the
breakpoints (fig. 3C). This finding suggested either dis-
ruption or duplication of the YACs. On FISH with plas-
mids containing the 5′ and 3′ ends of the PLP gene,
signals were observed on both arms of the inverted X
chromosome. This is consistent with a duplication of the
PLP gene near the inversion breakpoints.
Molecular analysis.—PLP genomic organization was
investigated by Southern blotting with PLP cDNA and
genomic probes, after digestions with multiple enzymes
and standard and pulsed-field gel analysis. Probes de-
rived from the upstream region and from within the PLP
gene did not demonstrate any abnormal pattern. Ad-
ditionally, sequencing of the gene showed no mutations
within the coding sequences. The patient and his mother
were homozygous for the AhaII dimorphism of exon 4,
the CA-dinucleotide repeat of the first intron, and the
MvaI polymorphism of exon 2 (data not shown).
Family 3
Cytogenetic analysis.—The FISH result was reported
in Woodward et al. (1998). In addition to the normal
copy of PLP in Xq22, a copy was found in Xq26. The
patient’s mother also carried this change; however, she
was a somatic chromosomal mosaic. Approximately half
her cells contained two X chromosomes that were cy-
togenetically normal, but one chromosome had a single
copy of PLP at Xq22, and the other chromosome had
copies of the gene at Xq22 and Xq26. The other half
of the cells contained a cytogenetically normal X chro-
mosome with a single copy of PLP at Xq22 and a par-
tially deleted X chromosome in which the PLP gene was
missing. Therefore, the mother’s cells contained either
three copies of PLP or one copy of the gene. The ma-
ternal grandmother’s chromosomes were normal by kar-
yotype and FISH analysis.
Discussion
Nature of Sequences and Event
There is an increasing awareness that genomic in-
stability arises from homologous recombination that
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Figure 3 FISH analysis of the families. Metaphase chromosome spread (A) and interphase nucleus (B) from the propositus in figure 1A,
as hybridized with a PLP cosmid probe (yellow) and an X chromosome centromeric probe (red). The signal on chromosome Xq22 shows the
normal PLP gene, and the signal on Xp22.1 shows the PLP duplication. The two clearly resolvable yellow signals in the interphase nucleus
show the PLP duplication on either side of the red centromeric signal. C, Metaphase chromosome spread from the propositus in family 2.
Hybridization was with the YAC 122e11 probe. D, Single PLP signal from control metaphase spread.
occurs at low-copy-number repeats. This has been
shown to give rise to a number of genetic disorders.
The majority of these disorders—including the Prader-
Willi/Angelman, DiGeorge/velo-cardio-facial, and Wil-
liams syndromes and hereditary liability to pressure
palsies—result from deletions of the regions between
the repeats. In contrast, Charcot-Marie-Tooth type 1A
(CMT1A) is a well-characterized example of duplica-
tion leading to a genetic disorder (as reviewed in Har-
ding [1995]). There are many points of similarity be-
tween the duplications in the CNS neuropathy (PMD)
and those in the peripheral neuropathy (CMT1A).
However, the results presented here show that the du-
plications that result in the additional copy of the PLP
gene can arise by a mechanism different from homol-
ogous recombination that is mediated by low-level re-
peats. The finding, obtained by metaphase FISH anal-
ysis of the duplicated sequences in several different X
chromosome bands, must involve excision from the X
chromosome. Such a mechanism would require at least
three DNA breaks. Although the sequence in and
around PLP is being determined (GenBank Genetic Se-
quence Database and The Sanger Centre), to date noth-
ing is known about the nature of the DNA sequences
at the site of insertions.
Origin of the Extra Copy
Available evidence suggests that the duplication in
PMD arises most commonly as the result of an intra-
chromosomal event. Heterozygosity of the AhaII di-
morphism in an affected male has been observed only
in the family reported here, despite the fact that the
average heterozygosity of the marker is 0.38 and that
20 affected males from different families have been
studied. The finding of AhaII heterozygosity in family 1
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could have two explanations: either there was a dupli-
cation event (intrachromosomal), followed by mutation
at the site, or the dimorphism arose from two separate
copies of the gene, each of which carried a different
AhaII variant. Analysis of four multiallelic markers
within the duplicated region shows homozygosity
throughout the region for most patients (Woodward et
al. 1998); however, the propositus was also heterozygous
for the CA repeat within the PLP gene and for DXS8096
within the duplication. Such heterozygosity for multiple
markers is more consistent with an interchromosomal
duplication event (i.e., between unlike chromosomes)
than with an intrachromosomal event followed by mu-
tation at the AhaII site. Thus, it is our contention that
the more likely explanation is that the AhaII heterozy-
gosity arose as a result of recombination between two
X chromosomes in a female, with each chromosome
carrying a different form of the dimorphism. Direct ev-
idence that the extra copy can be acquired from the other
female X chromosome is available in family 3 (Wood-
ward et al. 1998). This was the only case, among the
series of duplications reported, in which multiallelic
polymorphic markers from within the duplication were
found to be heterozygous. The duplication arose de novo
in the mother of the propositus (unpublished results).
The propositus (patient IV-1) in family 1 is a member
of a four-generation family with proved PMD in each
of the last three generations. In a normal situation, re-
combination between the gene copies on the long and
short arms would be expected. Comparison of the hap-
lotypes of markers along the X chromosome in the pro-
positus and his affected uncle show that there have in-
deed been recombinants (data not presented). Each
affected male member of the family is also heterozygous
for the polymorphism. This suggests that the “extra
copy” (on Xp) carries the less common (frequency .25)
AhaII  variant, whereas the “normal” copy (on Xq)
is most likely the common (frequency .75) AhaII allele.
In family 2, the propositus and his presumed carrier
mother were homozygous for the AhaII dimorphism in
exon 4, the MvaI polymorphism in exon 2, and the CA-
dinucleotide repeat in the first intron of the PLP gene.
Although this is consistent with an intrachromosomal
origin of the duplication, an interchromosomal exchange
cannot be ruled out.
At this time, the mechanism by which the duplicated
copies of PLP arose is not understood. Although several
disorders are known to involve deletion or duplication
based on low-copy-number repeats, the investigations of
mechanism are new. Such is the current status of PLP
duplications.
Stability of the Resulting Chromosome
The origin of the X chromosome carrying the dupli-
cation in family 2 is unknown, although examination of
the pedigree indicates stable transmission of the inv(X)
from the mother (patient I-2; fig. 1B) to four of her five
children. The pedigree also provides circumstantial ev-
idence that an abnormal chromosome is carried by at
least three generations, since there is a history of “ce-
rebral palsy” in the maternal uncle of the propositus.
However, samples have not been available for chro-
mosome analysis of the mother’s brother or mother.
Wider Implications
It is entirely unclear why the additional copy should
be located, in each case, on the X chromosome. There
is no known tendency for pairing between Xq22 and
the three regions involved. If the additional copy were
located on an autosome, there would be an equal chance
of its affecting a female. It may be that, since females
have not been routinely tested for the PLP duplication,
such cases, which are expected to be rare, have been
missed.
As far as we know, the situation in which patients
have a noncontiguous duplication, as observed in the
present study, is unprecedented. Questions arise as to
how commonly such undetected submicroscopic trans-
positions occur and what clinical outcomes might be
expected. Several factors have led to the fortuitous ob-
servation of these PLP duplications. First, PLP is one
of only a very small number of known genes that are
dosage-sensitive to an extra copy, and this was examined
only because of analogies with the PMP-22 gene in he-
reditary motor and sensory neuropathy type 1 (Ellis and
Malcolm 1994). CMT1A, which is a peripheral neu-
ropathy that results in demyelination, is usually caused
by duplication of the PMP-22 gene, which lies in the
center of the 1.5-Mb duplicated segment. The duplica-
tion results in an additional (third) copy of the PMP-22
gene, which is disease causing. Second, extra copies are
easier to detect on the X chromosome than on an au-
tosome. Third, not only must the gene be subject to
dosage sensitivity, but it must lie within a region of the
genome where there are factors operating at the chro-
mosomal level that drive the formation of a duplication.
For CMT1A, on chromosome 17, the breakpoints lie
well outside the PMP-22 coding region, and not only
are they detectable by pulsed-field gel electrophoresis
(Raeymaekers et al. 1992), but they have been shown
to lie within a hotspot for recombination (Kiyosawa et
al. 1995; Lopes et al. 1998; Reiter et al. 1998). The
rearrangement leads to tandem repeats only. The only
exceptions have been cytogenetically visible duplications
in patients with multiple abnormalities, including signs
of Charcot-Marie-Tooth disease (Chance et al. 1992;
Upadhyaya et al. 1993; Pellegrino et al. 1996), analo-
gous to the published example involving PMD (Cremers
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et al. 1987). No case in which the 1.5-Mb segment is
translocated to a distant locus has been reported.
It is possible that other examples exist in which such
submicroscopic rearrangements have occurred but have
remained undetected because the favorable factors of
gene-dosage sensitivity and chromosomal environment
have not occurred together. One way in which insertions
might be found is during large-scale linkage projects that
use closely linked markers. International collaborations
to map the CMT1A gene foundered for some time, be-
cause of apparent inconsistency of marker order, until
the existence of the duplication was appreciated (Nich-
olson et al. 1992). Such insertions have not been re-
ported, but there may be underreporting of “unexplai-
ned” findings. Transposed sequences could be detected
if they inserted, by chance, into a coding region of a
structural gene that was under intense analysis because
of its known role in genetic disease. Examples, although
rare, were reported for Alu (Oldridge et al. 1999 [and
references therein]) and LINE (Kazazian 1998 [and ref-
erences therein]) repeats. It is likely that other examples
of the insertions described here are less common but may
occur. A further possibility is that insertions may occur
but may not contain dosage-sensitive genes. They may
exert an effect by disruption of sequences at the insertion
point or by a position effect (Kleinjan and van Heyingen
1998). With the exception of patient II-3 (see fig. 1B),
who has Down syndrome in addition to PMD, the clin-
ical features in the patients with PMD who are presented
here were within the usual range. Thus, it is likely that
no important sequences were disrupted. This may not
always be the case.
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